by Steven R. Feldman, MD, PhD; Joel M. Gelfand, MD, MSCE; and Alice B. Gottlieb, MD, PhD
Patients with moderate to severe plaque psoriasis may be at an increased risk for psoriatic arthritis, metabolic dysregulation, and cardiovascular ......READ MORE
A significant percentage of individuals with psoriasis are women of childbearing age, which can pose a number of treatment challenges. The timely i......READ MORE
Nonadherence to psoriasis treatment is common and leads to negative therapeutic outcomes. Multiple approaches may be needed to encourage patients t......READ MORE
by Steven R. Feldman, MD, PhD; Joel M. Gelfand, MD, MSCE; and Alice B. Gottlieb, MD, PhD
With many different highly effective therapies now available, clinicians and their patients with plaque psoriasis can aim high in achieving their s......READ MORE
Patient preferences can have a significant impact on treatment adherence, patient satisfaction, and, ultimately, treatment success. When treating t......READ MORE
Interleukin 23 (IL-23) plays an important role in the development of psoriatic disease, and IL-23 inhibitors are effective and well tolerated for t......READ MORE
